Wachovia Keeps 'Outperform' on Nabi Biopharmaceuticals

Analyst Martin Auster says the drugmaker accelerated its timeline for a lead pipeline drug

Wachovia reiterates outperform on Nabi Biopharmaceuticals (NABI ).

To continue reading this article you must be a Bloomberg Professional Service Subscriber.